ProQR Therapeutics NV
NASDAQ:PRQR

Watchlist Manager
ProQR Therapeutics NV Logo
ProQR Therapeutics NV
NASDAQ:PRQR
Watchlist
Price: 3.62 USD 0.28% Market Closed
Market Cap: 383.4m USD
Have any thoughts about
ProQR Therapeutics NV?
Write Note

ProQR Therapeutics NV
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ProQR Therapeutics NV
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
ProQR Therapeutics NV
NASDAQ:PRQR
Change in Working Capital
-€8.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Change in Working Capital
-$12.9m
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
1%
Uniqure NV
NASDAQ:QURE
Change in Working Capital
-$12.1m
CAGR 3-Years
24%
CAGR 5-Years
-54%
CAGR 10-Years
-38%
argenx SE
XBRU:ARGX
Change in Working Capital
-$260m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Change in Working Capital
$23.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Change in Working Capital
-$2.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ProQR Therapeutics NV
Glance View

Market Cap
383.4m USD
Industry
Biotechnology

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

PRQR Intrinsic Value
2.41 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is ProQR Therapeutics NV's Change in Working Capital?
Change in Working Capital
-8.3m EUR

Based on the financial report for Sep 30, 2024, ProQR Therapeutics NV's Change in Working Capital amounts to -8.3m EUR.

Back to Top